Skip to main content
SpringerLink
Log in

Parkinson’s Disease: Outcome Variables and Clinical Scales

  • Chapter
Clinical Trials in Neurology

  • 265 Accesses

Abstract

Parkinson’s disease is a progressive disorder characterised by tremor, rigidity, bradykinesia and postural instability. The aetiology, pathophysiology and clinical features all have a bearing on the selection of appropriate outcome measures and will be discussed briefly.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Marsden CD. Parkinson’s disease. Lancet 1990; 335: 948–952.

    Article  PubMed  CAS  Google Scholar 

  2. Mann DMA, Yates PO. Possible role of neuromelanin in the pathogenesis of Parkinson’s disease. Mechanisms Ageing Dev 1983; 21: 193–203.

    Article  CAS  Google Scholar 

  3. Barbeau A. Aetiology of Parkinson’s disease: a research strategy. Can J Neurol Sci 1984; 11: 24–28.

    PubMed  CAS  Google Scholar 

  4. Koller WC, Langston JW, Hubble JP, Irwin I, Zack M, Golbe L, et al. Does a long preclinical period occur in Parkinson’s disease? Neurology 1991; 41 (Suppl 2): 8–13.

    Article  PubMed  CAS  Google Scholar 

  5. McGreer PL, et al. Rate of cell death in Parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24: 574576.

    Google Scholar 

  6. Fearnley JM, Less AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991; 114: 2283 2301.

    Google Scholar 

  7. Gibb WRG, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 1989; 15: 27–44.

    Article  PubMed  CAS  Google Scholar 

  8. Alexander GE, DeLong MR, Strick PL. Parallel organisation of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357–381.

    Article  PubMed  CAS  Google Scholar 

  9. Alexander GE, Cruthcher MD, DeLOng MR. Basal ganglia thalamo-cortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. Prog Brain Res 1990; 85: 119–146.

    Article  PubMed  CAS  Google Scholar 

  10. Duvoisin RC. The differential diagnosis of parkinsonism. In: Stern G, editor. Parkinson’s disease. London: Chapman and Hall Medical, 1990: 431–466.

    Google Scholar 

  11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–184.

    Article  PubMed  CAS  Google Scholar 

  12. Ansorge O, Lees AJ, Daniel SE. Update on the accuracy of clinical diagnosis of idiopathic Parkinson’s disease. Mov Disord 1997(Suppl):359.

    Google Scholar 

  13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.

    Article  PubMed  CAS  Google Scholar 

  14. The Parkinson Study Group. Effect of Deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–1371.

    Article  Google Scholar 

  15. Poewe WH, Wenning GK. The natural history of Parkinson’s disease. Neurology 1996; 47: (Suppl 3): S146–152.

    Article  PubMed  CAS  Google Scholar 

  16. Bonnet AM, Loria Y, Saint-Hilatre, Lhermitte F, Agid Y. Does long term aggravation of Parkinson’s disease result from nondopaminergic lesions? Neurology 1987; 37: 1539–1542.

    Article  PubMed  CAS  Google Scholar 

  17. Goetz CG, Tanner CM, Shannon KM. Progression of Parkinson’s disease without levodopa. Neurology 1987; 37: 695–698.

    Article  PubMed  CAS  Google Scholar 

  18. Ben Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology. J Neurol Neurosurg Psychiatry 1995; 58: 293–299.

    Article  Google Scholar 

  19. Brown RG, Marsden CD. Neuropsychology and cognitive function in Parkinson’s disease: an overview. In: Marsden CD, Fahn S, editors. Movement disorders 2. London: Butterworth 1987.

    Google Scholar 

  20. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49: 381–389.

    Article  PubMed  CAS  Google Scholar 

  21. Marsden CD, Parkes JD. On-off effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1976; I: 29 2296.

    Google Scholar 

  22. Juncos JL, Engber TM, Raisman R, Susel Z, Thibaut F, Ploska A, et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989; 25: 473–478.

    Article  PubMed  CAS  Google Scholar 

  23. Madrazo I, et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson’s disease. N Engl J Med 1988; 332: 1118–1124.

    Google Scholar 

  24. Lindvall O, Widner H, Rehncrona S, et al. Transplantation of foetal dopamine neurones in Parkinson’s disease: one year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992; 31: 155–165.

    Article  PubMed  CAS  Google Scholar 

  25. Harby K. Using fetus derived tissues for molecular medicine: tension between research and ethics. Mol Med Today 1996; 2: 326–329.

    Article  PubMed  CAS  Google Scholar 

  26. Boer GJ. Ethical guidelines for the use of human embryonic or foetal tissue for experimental and clinical neurotransplantation and research. Network of European CNS Transplantation and Restoration (NECTAR). J Neurol 1994; 242: 1–13.

    Article  PubMed  CAS  Google Scholar 

  27. Northoff G. Do brain tissue transplants alter personality? Inadequacies of some standard arguments. J Med Ethics 1996; 22: 174–180.

    Article  PubMed  CAS  Google Scholar 

  28. World Health Organization. International classification on impairments, disability and handicaps. Geneva: WHO, 1980.

    Google Scholar 

  29. Diamond SG, Markham CH. Evaluating the evaluations: or how to weigh the scales of parkinsonian disability. Neurology 1983; 33: 1098–1099.

    Article  PubMed  CAS  Google Scholar 

  30. Henderson L, Kennard C, Crawford TJ, et al. Scales for rating motor impairment in Parkinson’s disease: studies of reliability and convergent validity. J Neurol Neurosurg Psychiatry 1991; 54: 18–24.

    Article  PubMed  CAS  Google Scholar 

  31. Ward CD, Sanes JN, Dambrosia JM, Calne DB. Methods for evaluating treatment in Parkinson’s disease. In: Fahn S, Calne DB, Shoulson I, editors. Experimental therapeutics of movement disorders. Advances in neurology 37. New York: Raven Press, 1983.

    Google Scholar 

  32. Caligiuri MR. Portable device for quantifiying parkinsonian wrist rigidity. Mov Disorders 1994; 9: 57–63.

    Article  CAS  Google Scholar 

  33. Jankovic J, Frost JD. Quantitative assessment of parkinsonian and essential tremor: clinical application of tri-axial accelerometry. Neurology 1980; 30: 393.

    Google Scholar 

  34. Marsden CD, Schachter M. Assessment of extrapyramidal disorders. Br J Clin Pharmacol 1981; 11: 129–151.

    Article  PubMed  CAS  Google Scholar 

  35. Jankovic J, Lang AC, Fahn S. High technology in the quantitation of movement disorders. Ninth international symposium on Parkinson’s disease, 1988.

    Google Scholar 

  36. Lakke JPWF. Assessment and measurement. In: Stern G, editor. Parkinson’s disease. London: Chapman and Hall Medical, 1990: 467–491.

    Google Scholar 

  37. Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Bannister R, et al. Striatal D2 receptor status in Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with “C-raclopride and PET. Ann Neurol 1992; 31: 184–192.

    Article  PubMed  CAS  Google Scholar 

  38. Playford ED, Brooks DJ. In vivo and in vitro measurements of the dopaminergic system in movement disorders. Cerebrovasc Brain Metab Rev 1992; 4: 144–171.

    PubMed  CAS  Google Scholar 

  39. Garnett ES, Firnau G, Nahmias C. Dopamine visualised in the basal ganglia of living man. Nature 1983; 305: 137–138.

    Article  PubMed  CAS  Google Scholar 

  40. Vingerhoets FJG, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB. Positron emission tomographic evidence for progression of human MPTP induced dopaminergic lesions. Ann Neurol 1994; 36: 765–770.

    Article  PubMed  CAS  Google Scholar 

  41. Pate BD, Kawamata T, Yamada T, McGreer EG, Hewitt KA, Snow BJ, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993; 34: 331–338.

    Article  PubMed  CAS  Google Scholar 

  42. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, et al. The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, primary autonomic failure and Parkinson’s disease studied with PET. Brain 1990; 113: 1539–1552.

    Article  PubMed  Google Scholar 

  43. Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I, et al. Input functions for 6-(fluorine-18)fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med 1994; 35: 955–963.

    PubMed  CAS  Google Scholar 

  44. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease Brain 1996; 119: 585–591.

    Google Scholar 

  45. Sawle GV, Bloomfield PM, Bjorklund A, et al. Transplantation of foetal dopamine neurones in Parkinson’s disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol 1992; 31: 166–173.

    Article  PubMed  CAS  Google Scholar 

  46. Snow BJ, Tooyama I, Mcgreer EG, et al. Correlations in humans between postmortem PET fluorodopa uptake, postmortem dopaminergic cell counts and striatal dopaminergic levels. Ann Neurol 1993; 34: 324–330.

    Article  PubMed  CAS  Google Scholar 

  47. Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991: 456.

    Google Scholar 

  48. Wade DT. Measurement in neurological rehabilitation. Oxford: Oxford University Press, 1992.

    Google Scholar 

  49. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1972; 1: 233–238.

    Article  PubMed  CAS  Google Scholar 

  50. Katzman R, Brown T, Fuld P, Peck A, Schecter R, Schimmel H. Validation of a short Orientation-Memory-Concentration test of cognitive impairment. Am J Psychiatry 1983; 140: 734–739.

    PubMed  CAS  Google Scholar 

  51. McDowell F, Lee JE, Swift T, Sweet RD, Ogsbury JS, Kessler T. Treatment of parkinson’s syndrome with L-dihydroxyphenylalanine (levodopa). Ann Intern Med 1970; 72: 29–35.

    PubMed  CAS  Google Scholar 

  52. Yahr MD, Duvoisin RC, Schear MJ, et al. Treatment of Parkinsonism with levo-dopa. Arch Neurol 1969; 21: 343–354.

    Article  PubMed  CAS  Google Scholar 

  53. Lieberman AN. Parkinson’s disease: a clinical review. Am J Med Sci 1974; 267: 66–80.

    Article  PubMed  CAS  Google Scholar 

  54. Webster DD. Critical analysis of the disability in Parkinson’s disease. Mod Treatment 1968; 5: 257–282.

    CAS  Google Scholar 

  55. Alba A, Trainor FS, Ritter W, Dacso MM. A clinical rating scale for Parkinson patients. J Chron Dis 1968; 21: 507–522.

    Article  PubMed  CAS  Google Scholar 

  56. Fahn S, Elton RL, and members of the UPDRS Development Committee. In: Fahn S, Marsden CD, Caine DB, Goldstein M, editors. Recent developments in Parkinson’s disease, vol 2. Florham Park, NJ: MachMillan Health Care Information, 1983: 153–165.

    Google Scholar 

  57. Hely MA, Chey T, Wilson A, et al. Reliability of the Columbia scale for assessing signs in Parkinson’s disease. Mov Disord 1993: 8: 466–472.

    Article  PubMed  CAS  Google Scholar 

  58. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson’s Disease Rating Scale Motor Examination. Mov Disord 1994; 9: 89–91.

    Article  PubMed  CAS  Google Scholar 

  59. Louis ED, Lynch T, Marder K, Fahn S. Reliability of patient completion of the historical section of the unified Parkinson’s disease rating scale. Mov Disord 1996; 11: 185–192.

    Article  PubMed  CAS  Google Scholar 

  60. Martinez-Martin P, Gil-Nagel A, Morlan Gracia L, Balseiro Gomez J, Martinez-Sarries J, Bermejo F, and the Co-operative Multicentric Group. Unified Parkinson’s disease rating scale characteristics and structure. Mov Disord 1994; 9: 76–83.

    Article  Google Scholar 

  61. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361–370.

    Article  PubMed  CAS  Google Scholar 

  62. Folstein MF, Folstein SE, McHugh PJ. “Mini-mental state”: a practical method for grading the cognitive state of patients for clinicians. J Psychiatr Res 1975; 12: 189–198.

    Article  PubMed  CAS  Google Scholar 

  63. Reynold NC, Montgomery GK. Factor analysis of Parkinson’s impairment: an evaluation of the final common pathway. Arch Neurol 1987; 44: 1013–1016.

    Article  Google Scholar 

  64. Van Hilten JJ, van der Zwan AD, Zwinderman AH, Roos RA. Rating impairment and disability in Parkinson’s disease: evaluation of the Unified Parkinson’s Disease Rating Scale. Mov Disord 1994; 9: 84–88.

    Article  PubMed  Google Scholar 

  65. Langston JW, Widner H, Goetz CG, et al. Core Assessment Program for Intracerebral Transplantation (CAPIT). Mov Disord 1992; 7: 2–13.

    Article  PubMed  CAS  Google Scholar 

  66. Canter GJ, De la torre R, Mier M. A method for evaluating disability in patients with Parkinson’s disease. J Nery Ment Dis 1961; 133: 143–147.

    Article  CAS  Google Scholar 

  67. Brown RG, MacCarthy B, Jahanshahi M, Marsden CD. Accuracy of self reported disability in patients with parkinsonism. Arch Neurol 1989; 46: 955–959.

    Article  PubMed  CAS  Google Scholar 

  68. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Maryland State Med J 1965; 14: 61–65.

    CAS  Google Scholar 

  69. Wade DT, Collin C. The Barthel ADL index: a standard measure of physical disability? Int Disability Studies 1988; 10: 64–67.

    Article  CAS  Google Scholar 

  70. Nonni FM, Lincoln NB. An extended activities of daily living scale for stroke patients. Clin Rehabil 1987; 1: 301–305.

    Article  Google Scholar 

  71. Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for the nine hole peg test of finger dexterity. Occup Ther J Res 1985; 5: 24–37.

    Google Scholar 

  72. Yekutiel MP, Pinhasov A, Shahar G, Sroka H. A clinical trial of the re-education of movement in patients with Parkinson’s disease. Clin Rehabil 1991; 5: 207–214.

    Article  Google Scholar 

  73. Nieuwboer A, et al. Is using a cue the clue to the treatment of freezing in Parkinson’s disease? Physiother Res Int 1997; 2: 125–132.

    Article  PubMed  CAS  Google Scholar 

  74. A symposium on the minimal record of disability. Acta Neurol Scand 1984; 101 (Suppl): 167–207.

    Google Scholar 

  75. Hunt SM, McKenna SP, McEwan J, et al. A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health 1980; 34: 281–286.

    Article  PubMed  CAS  Google Scholar 

  76. Schindler JS, Brown R, Welburn P, Parkes JD. Measuring the quality of life in patients with Parkinson’s disease. In: Walter SR, Rosser R, editors. Quality of life: assessment and application. Lancaster: MTP Press, 1987: 223–234.

    Google Scholar 

  77. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993; 306: 1437–1440.

    Article  PubMed  CAS  Google Scholar 

  78. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS. BMJ 1993; 306: 1440 1444.

    Google Scholar 

  79. Peto V, Fitzpatrick R, Jenkinson C. Self reported health status and access to health services in a community sample with Parkinson’s disease. Disabil Rehabil 1997; 19: 97103.

    Article  Google Scholar 

  80. Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N. Self reported functioning and well-being in patients with Parkinson’s disease: comparison of the short-form health survey (SF36) with the Parkinson’s disease questionnaire (PDQ 39). Age Ageing 1995; 24: 505–509.

    Article  PubMed  CAS  Google Scholar 

  81. Schwartz D, Flanmant R, Llelouch J. Clinical trials. New York: Academic Press, 1991.

    Google Scholar 

  82. Ward CD. Does selegiline delay progression of Parkinson’s disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994; 57: 217–220.

    Article  PubMed  CAS  Google Scholar 

  83. Lang AE, Quinn N, Brincat S, Marsden CD, Parkes JD. Pergolide in late stage Parkinson’s disease. Ann Neurol 1982; 12: 243247.

    Google Scholar 

  84. Tanner GM, Goetz CG, Glantz RH, Glatt SL, Klawans HL. Pergolide mesylate and idiopathic Parkinson disease. Neurology 1982; 32: 1175–1179.

    Article  PubMed  CAS  Google Scholar 

  85. Lieberman A, Goldstein M, Leibowitz M. The effect of pergolide on the cardiovascular system of forty patients with Parkinson’s disease. Adv Neurol 1984; 37: 121–130.

    Google Scholar 

  86. Olanow CW, Fahn S, Muenter M, et al. A multicenter Intracerebral Transplantation [letter]. Mov Disord 1995;10:double blind placebo-controlled trial of Pergolide as an 527–528.

    Google Scholar 

  87. Obeso JA, Guridi J, DeLong M. Surgery for Parkinson’s disease. 1994; 117: 1169–1181.

    Google Scholar 

  88. Lang AE, Benabid A-L, Koller WC, Lozano AM, Obeso JA, Olanow CW, Pollak P. The Core Assessment Program for Intracerebral Transplantation [letter]. Mov Disord 1995;10: 527-528.

    Google Scholar 

  89. ME, lansek R, Matyas TA, Summers JJ. The pathogenesis of gait hypokinesia in Parkinson’s disease. Brain 1994;117:1169-1181.

    Google Scholar 

  90. . Margitic SE, Morgan TM, Sager MA, Furberg CD. Lessons learned from a prospective metanalyis. J Am Geriatr Soc 1995;43:435-439.

    Google Scholar 

Download references

Authors
  1. E. D. Playford
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neuromuscular Unit, West London Neurosciences Centre, 1st Floor Pilot Wing, Charing Cross Hospital, Fulham Palace Road, W6 8RF, London, UK

    Roberto J. Guiloff MD, FRCP (Consultant Neurologist) (Consultant Neurologist)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag London

About this chapter

Cite this chapter

Playford, E.D. (2001). Parkinson’s Disease: Outcome Variables and Clinical Scales. In: Guiloff, R.J. (eds) Clinical Trials in Neurology. Springer, London. https://doi.org/10.1007/978-1-4471-3787-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-3787-0_25

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84996-856-0

  • Online ISBN: 978-1-4471-3787-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation